N/A N=68 Heart Rate Variability Biofeedback: It's Role in Asthma Therapeutics
Asthma
Primary: Magnitude Change of Airway Reactivity Measured by Methacholine PC20FEV1 — 2.9782; 2.1181 mg/ml — p=>0.1
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=581 Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients
HIV Infections
Primary: Serious Adverse Events — 0; 17; 0; 6 Participants
Phase 2 N=9 CT Antigen TCR-redirected T Cells for Ovarian Cancer.
Ovarian Cancer
Primary: Adverse Events Related to Study Treatment — 5 Participants
N/A N=170 Optimizing Dose of Bupivacaine in Combined Spinal Epidurals To Reduce Side Effects
Pregnancy
Primary: Maternal Blood Pressure — 78.2; 79.58; 80.52 mm/Hg
N/A N=40 Clinical Outcomes Study Using a New Implantable Neurostimulation System for Chronic Intractable Pain
Chronic Pain
Primary: Proportion of Subjects Satisfied With Treatment at 90 Days Post-IPG Implantation — 32 Participants
Phase 2 N=25 Redirected Auto T Cells for Advanced Myeloma
Multiple Myeloma
Primary: Adverse Events Related to Study Treatment — 24 participants
Phase 2 N=22 Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib
Lung Cancer
Primary: Maximally Tolerated Dose (MTD) (Phase I) — 150; 20 mg
N/A N=32 Changes in Exhaled 13CO2/12CO2 Breath Delta Value as an Early Indicator of Infection in ICU Patients
Sepsis
Primary: Change in Breath Delta Value — 0.44 parts per mil (‰)
Phase 2 N=40 Clobetasol for Oral Graft-Versus-Host Disease
Oral Chronic Graft vs Host Disease
Primary: Percentage of Participants With a Response as Assessed by the 273-point Oral Mucositis Rating Scale (OMRS) Who Received Topical Clobetasol 0.05% Oral Rinse for Oral…
N/A N=3 A Brain Centered Neuroengineering Approach for Motor Recovery After Stroke: Combined rTMS and BCI Training
Hemiparesis · Stroke
Primary: Changes in Cortical Excitability and Cortical Activation Patterns as Measured by MRI and Functional MRI — 0.71; 0.72; -0.25; 0.81 Laterality index
Phase 3 N=329 Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel
Breast Cancer
Primary: Percentage of Participants With Total Pathologic Complete Response (tpCR) as Assessed by the Independent Review Committee (IRC) — 39.3; 21.8 percentage of participants…
Phase 2 N=7 A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Non-Small Cell Lung Cancer · Breast Cancer · Pancreatic Cancer
Primary: Phase 1b: Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Durvalumab (MEDI4736) and to Find the Recommended Phase II…
Phase 2 N=50 Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Breast Cancer
Primary: Progression-Free Survival (PFS) — 3.7; 3.6 months — p=0.79
Phase 2 N=55 Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery
Recurrent Renal Cell Carcinoma · Stage III Renal Cell Cancer · Stage IV Renal Cell Cancer
Primary: Response Rate (Confirmed Complete Response or Partial Response), Determined According to Response Evaluation Criteria in Solid Tumors — 0; 0; 0; 0 Participants
Phase 2 N=7 18F-FSPG PET/CT for Cancer Patients on Therapy
B-Cell Neoplasm · Estrogen Receptor Negative · HER2/Neu Negative
Primary: Change From Baseline in Standard Uptake Value Maximum (SUVmax) Post-treatment — -1.69; -0.64 g/mL